Here are the latest semaglutide news highlights I found across reputable sources:
Novo Nordisk has released updates suggesting semaglutide may be effective against liver disease associated with obesity and overweight, with upcoming data expected to address broader metabolic benefits. This was highlighted by Novo Nordisk in their latest newsroom communications. [Source: Novo Nordisk newsroom, 2026-05-18]
The SOUL trial for oral semaglutide (Rybelsus) reported cardiovascular event reductions in patients with established cardiovascular disease, potentially expanding oral GLP-1 options for some patients. This was discussed in recent industry analyses and podcasts summarizing trial results. [Source: podcast summary on semaglutide updates, 2024-11-13]
Industry press and market coverage through 2025–2026 note ongoing expansion plans for semaglutide therapies, including potential launches in new regions and the progression of oral and injectable formulations through Phase III and regulatory review. [Source: Economic Times coverage referencing Phase III trials and potential future launches, 2025-08-22]
In clinical research, updates through 2026 point to broader applications beyond weight management, including potential benefits for liver disease and metabolic conditions, with continued interest from researchers and payers in widening access. [Source: Dose GLP-1 news digest, 2026-04-18]
Public safety and regulatory monitoring continue for semaglutide products, including concerns around compounded or counterfeit formulations and ongoing pharmacovigilance updates. Patients and clinicians are advised to verify product sourcing and authenticity. [Source: novoMEDLINK patient safety updates, 2024-12-17]
If you’d like, I can narrow this to:
Find Semaglutide Weight Loss Latest News, Videos & Pictures on Semaglutide Weight Loss and see latest updates, news, information from NDTV.COM. Explore more on Semaglutide Weight Loss.
www.ndtv.comGet all latest & breaking news on Semaglutide. Watch videos, top stories and articles on Semaglutide at moneycontrol.com.
www.moneycontrol.comحلقة بودكاست · Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · ١٢/٠٥/١٤٤٦ هـ · ٢٥د
podcasts.apple.comGlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.
www.globenewswire.comMedical and health news service that features the most comprehensive coverage in the fields of neuroscience, cardiology, cancer, HIV/AIDS, psychology, psychiatry, dentistry, genetics, diseases and conditions, medications and more.
medicalxpress.comFDA actions, trial results, and safety updates for Ozempic, Wegovy, Mounjaro, and Zepbound.
doseglp1.comsemaglutide Latest Breaking News, Pictures, Videos, and Special Reports from The Economic Times. semaglutide Blogs, Comments and Archive News on Economictimes.com
economictimes.indiatimes.comGet the latest patient safety updates on compounded and counterfeit semaglutide. Learn more about Novo Nordisk medications containing semaglutide.
www.novomedlink.comSemaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.
www.news-medical.netHere journalists can access a concise and up-to-date overview of our company’s key facts, figures, and milestones.
www.novonordisk.com